Narasimharaju SN, senior manager — regulatory affairs and Mac Kella, senior regulatory affairs executive at ELC Group assess whether biosimilars are really interchangeable in the EU.
Biological agents have revolutionised therapy and transformed treatment paradigms due to improved short- and long-term clinical and public health outcomes, and general patient care of chronic and debilitating autoimmune disorders.